Skip to main content

Advertisement

Table 1 Baseline characteristics of 294 patients with Candida bloodstream infection in the CHINA-SCAN study, according to CRCBSI and NCRCBSI

From: Catheter-related Candidabloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study

Variables CRCBSI NCRCBSI P-value
N = 29 N = 265
Age (years), mean ± SD 69.4 ± 19.1 60.7 ± 20.2 0.028*
Gender, n (%)    0.527
Male 22 (75.9) 181 (68.3)  
Female 7 (24.1) 84 (31.7)  
Body weight (kg), mean ± SD 58.0 ± 5.2 63.2 ± 11.0 0.037*
Symptoms, n (%)    
Fever 27 (93.1) 243 (91.7) 1.000
Shivers 8 (27.6) 83 (31.3) 0.833
Confusion 13 (44.8) 123 (46.4) 1.000
Concomitant disease, n (%)    
Type 1 or 2 diabetes 7 (24.1) 59 (22.3) 0.833
Chronic cardiac dysfunction 6 (20.7) 57 (21.5) 0.891
Solid tumor 8 (27.6) 45 (16.9) 0.180
Chronic obstructive pulmonary disease 4 (13.8) 31 (11.7) 0.762
Chronic renal insufficiency 5 (17.2) 27 (10.2) 0.259
Chronic hepatic insufficiency 4 (13.8) 12 (4.5) 0.060
Hematological malignancy 0 (0.0) 3 (1.2) 1.000
Invasive procedures within 2 weeks prior to diagnosis, n (%)    
Hemodialysis 2 (6.9) 15 (5.7) 0.259
Invasive mechanical ventilation 24 (82.7) 204 (77.0) 0.666
Total parenteral nutrition 14 (48.3) 115 (43.4) 0.695
Surgery 11 (37.9) 102 (38.5) 1.000
Immunosuppression 2 (6.9) 15 (5.7) 0.679
Illness severity at ICU admission, mean ± SD    
APACHE II score 28.5 ± 7.6 27.0 ± 7.1 0.286
SOFA score 10.6 ± 2.9 11.2 ± 3.5 0.330
Illness severity at diagnosis, mean ± SD    
APACHE II score 28.2 ± 7.2 27.0 ± 7.0 0.360
SOFA score 9.8 ± 3.3 10.8 ± 3.5 0.147
Immune enhancement therapy, n (%)a 21 (72.4) 102 (38.5) <0.001**
Antibiotic use, n (%)    0.963
Monotherapy 8 (32.0) 75 (35.9)  
Two-drug combinations 13 (52.0) 98 (46.9)  
Three-drug combinations 4 (16.0) 35 (16.7)  
Antibiotic use period, mean ± SD 11.4 ± 4.2 10.6 ± 6.5 0.514
Antibiotic therapy >5 days, n (%) 25 (86.2) 209 (78.9) 0.469
Antifungal therapy, n (%) 28 (96.6%) 229 (86.4%) 0.118
Initial antifungal treatment, n (%)    0.977
Fluconazole 11 (39.3%) 84 (36.7%)  
Caspofungin 7 (25.0%) 54 (23.6%)  
Voriconazole 4 (14.3%) 44 (19.2%)  
Micafungin 3 (10.7%) 20 (8.7%)  
Itraconazole 3 (10.7%) 18 (7.9%)  
Amphotericin B (liposomes or lipid dispersions) 0 5 (2.2%)  
Two-drugs combinationb 0 4 (1.7%)  
Treatment duration, mean ± SD 19.0 ± 13.3 16.7 ± 13.3 0.338
Antifungal therapy >5 days, n (%) 8 (27.6) 70 (26.4) 1.000
Time between ICU admission and diagnosis of Candida infection (days), median (Q1,Q3) 11.0 (4.0, 26.0) 10.00 (4.0, 21.0) 0.544
  1. *P<0.05, **P<0.01.
  2. aUse of immunoglobulins and/or thymosin α1.
  3. bFluconazole + caspofungin: 2 patients; itraconazole + fluconazole: 1 patient; amphotericin B + caspofungin: 1 patient.
  4. CRCBSI: catheter-related Candida bloodstream infection; NCRCBSI: non-catheter-related Candida bloodstream infections; ICU: intensive care unit; APACHE: acute physiology and chronic health evaluation II; SOFA: sequential organ failure assessment.